APA (7th ed.) Citation

Chen, W., Fu, C., Fang, B., Liang, A., Xia, Z., He, Y., . . . Yang, Y. (2025). Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma. Experimental Hematology & Oncology, 14(1), 1. https://doi.org/10.1186/s40164-025-00710-y

Chicago Style (17th ed.) Citation

Chen, Wenming, et al. "Phase II Study of Zevorcabtagene Autoleucel, a Fully Human BCMA-targeting CAR T Cell Therapy, in Patients with Relapsed/refractory Multiple Myeloma." Experimental Hematology & Oncology 14, no. 1 (2025): 1. https://doi.org/10.1186/s40164-025-00710-y.

MLA (9th ed.) Citation

Chen, Wenming, et al. "Phase II Study of Zevorcabtagene Autoleucel, a Fully Human BCMA-targeting CAR T Cell Therapy, in Patients with Relapsed/refractory Multiple Myeloma." Experimental Hematology & Oncology, vol. 14, no. 1, 2025, p. 1, https://doi.org/10.1186/s40164-025-00710-y.